<DOC>
	<DOCNO>NCT00840853</DOCNO>
	<brief_summary>Subjects bone marrow SCT either type cancer blood call Leukemia cancer lymph node call non- Hodgkin 's Lymphoma . Although transplant cure leukemia lymphoma , people relapse . In relapse , current treatment cure small percentage . Although give patient dose donor immune cell relapse prevent relapse leukemia lymphoma , DLI also cause serious complication call graft versus host disease ( GVHD ) . This gene transfer research study use special immune cell specific cancer cell . The body different way fight infection disease . This study combine 2 way , antibody T cell . T cell ( CTLs cytotoxic T cell ) infection-fighting blood cell kill cell , include tumor cell . Antibodies T cell use treat patient cancer ; show promise , n't strong enough cure patient . The antibody use study call anti-CD19 . This antibody stick leukemia cell substance outside cell call CD19 . For study , anti-CD19 antibody change instead float free blood join T cell . When antibody join T cell way 's call chimeric receptor . In laboratory , investigator find T cell train recognize common virus stay blood stream many year . By join anti-CD19 antibody CTLs recognize virus , believe also able make cell last long time body , provide protection virus , recognize kill leukemia . The CTLs join anti-CD19 antibody attack 3 virus ( trivirus-specific CTLs ) , CMV , EBV , adenovirus . CMV virus rarely cause problem healthy people cause serious infection patient suppress immune system . It cause serious pneumonia , also affect intestinal tract , liver eye . 2/3 normal people harbor virus body . If subject donor positive CMV , subject risk develop CMV disease transplant . EBV cause mononucleosis `` mono '' ( infection fatigue , high fever , swollen lymph node ) . It normally control healthy immune system immune system weak bone marrow transplant cause fever , enlarge lymph node type cancer call lymphoma . Adenovirus virus cause symptoms common cold cause life-threatening infection patient weak immune system . Studies show trivirus-specific CTLs grown stem cell donor give safely transplant recipient stop virus cause severe infection . These CD19 chimeric receptor trivirus specific T cell investigational product approve FDA . The purpose study find big dose chimeric T cell safe , assess side effect , see long T cell last evaluate whether therapy might help prevent infection relapse people CD19+ leukemia lymphoma SCT .</brief_summary>
	<brief_title>Multi-virus CTLs Expressing CD19 Chimeric Receptors , CD19 Positive Malignancies Post SCT , MULTIPRAT</brief_title>
	<detailed_description>The donor give u blood make CD19 chimeric receptor trivirus specific T cell laboratory . These cell grow frozen subject . To make special T cell grown stimulator cell . Stimulator cell also make donor 's blood irradiate long grow . Stimulator cell infected virus carry proteins 3 virus ( CMV , adenovirus , EBV ) . These cell culture T cell learn see attack cell infect CMV , EBV adenovirus . To get CD19 antibody attach surface T cell , antibody gene insert T cell . This do virus call retrovirus make study carry antibody gene T cell . This virus also help find T cell blood inject . Once sufficient number T cell make , investigator freeze cell test make sure kill CD19+ tumor cell cell infected CMV , EBV adenovirus . Once test complete cell ready give subject . When subject enrolls study , assign dose CD19 chimeric receptor trivirus specific T cell . The subject give injection cell vein IV line assign dose . The injection take 20 minute . Investigators monitor subject clinic injection 3 hour . The treatment give Center Cell Gene Therapy Texas Children 's Hospital The Methodist Hospital . To learn way CD19 chimeric receptor trivirus specific T cell work long last body , extra blood drawn . The total blood drawn study exceed 300 tsp . For subject receive CTLs treatment disease : If subject stable disease ( tumor grow ) reduction size tumor image study blood count T-cell infusion , subject receive six additional dos T cell wish . After T-cell infusion , subject monitor . Because subject receive cell new gene subject follow total 15 year see long term side effect gene transfer .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Any patient regardless sex age CD19+ BALL undergo allogeneic HSCT ( Group A ) OR Any patient regardless sex age CD19+ BCLL NHL undergo allogeneic HSCT ( Group B ) . AND With minimal residual disease ( MRD ) relapse postHSCT ( phase I dose escalation ) OR With evidence ALL CLL/NHL postHSCT ( included expansion cohort 2 . Patients life expectancy great equal 6 week 3 . Patients Karnofsky/Lansky score great equal 50 4 . Donor HIV negative 5 . Patient parent/guardian capable providing inform consent 6 . Patients bilirubin 2x normal less , AST 3x normal less , creatinine le equal 2x normal age Hgb great 8.0 7 . Pulse oximetry great 90 % room air 8 . Sexually active patient must willing utilize one effective birth control method 6 month CTL infusion . The male partner use condom . 9 . Available allogeneic CD19CAR transduce trivirusspecific cytotoxic T lymphocytes great equal to15 % expression CD19CAR determine flowcytometry great 10 % kill one viral antigen pulse target cytotoxicity assay effector : target ratio 20:1 . * 10 . Patients investigational antiviral antitumor therapy one month prior entry study . Note : Cell dose base total cell number individual antivirus antileukemic cell number . EXCLUSION CRITERIA : 1 . Severe intercurrent infection 2 . Evidence graft versus host disease &gt; grade II 3 . Pregnant lactate 4 . History hypersensitivity reaction murine proteincontaining product . 5 . Currently take corticosteroid therapy GVHD .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Stem cell transplant</keyword>
	<keyword>Acute Lymphoblastic Leukemia ( ALL )</keyword>
	<keyword>Chronic Lymphocytic Leukemia ( CLL )</keyword>
	<keyword>Non Hodgkin 's Lymphoma</keyword>
	<keyword>Cytotoxic T lymphocyte</keyword>
	<keyword>CTL</keyword>
	<keyword>CD-19</keyword>
	<keyword>chimeric receptor</keyword>
</DOC>